Sensus Healthcare (SRTS) Resumen de Acciones
Sensus Healthcare, Inc. es una empresa de dispositivos médicos que fabrica y vende aparatos de radioterapia a profesionales sanitarios de todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
SRTS Community Fair Values
Create NarrativeSee what 64 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$13.42
FV
77.1% infravalorado descuento intrínseco20.39%
Revenue growth p.a.
1.6k
users have viewed this narrative6users have liked this narrative
0users have commented on this narrative
44users have followed this narrative
Competidores de Sensus Healthcare, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$3.07 |
| Máximo en las últimas 52 semanas | US$5.92 |
| Mínimo de 52 semanas | US$2.66 |
| Beta | 1.09 |
| Cambio en 1 mes | 8.10% |
| Variación en 3 meses | -25.30% |
| Cambio de 1 año | -34.12% |
| Variación en 3 años | -2.85% |
| Variación en 5 años | -19.42% |
| Variación desde la OPV | -47.52% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 22
SRTS: Future Upside Will Hinge On 2026 Margin Recovery
Analysts have trimmed their price target on Sensus Healthcare by $1 to $5.75, citing updated assumptions on long term profit margin and a lower future P/E multiple. What’s in the News for Sensus Healthcare Sensus Healthcare reported that from January 1, 2026 to March 31, 2026, the company repurchased 0 shares under its existing buyback program.
Actualización de narrativa • Jun 04
SRTS: 2026 Reimbursement Codes Will Support Long Term Earnings Potential
Analysts have reduced their price target on Sensus Healthcare by $1 to $6, reflecting a lower fair value estimate and sharply reduced profit margin assumptions, partly offset by expectations for continued revenue growth from the SRT platform, supported by new reimbursement codes planned for 2026. Analyst Commentary Recent research points to a more cautious tone around Sensus Healthcare, with the trimmed price target reflecting reduced profit margin assumptions, even as analysts still factor in potential revenue contribution from the SRT platform and future reimbursement changes planned for 2026.Actualización de narrativa • May 19
SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset
Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.Recent updates
Actualización de narrativa • Jun 22
SRTS: Future Upside Will Hinge On 2026 Margin Recovery
Analysts have trimmed their price target on Sensus Healthcare by $1 to $5.75, citing updated assumptions on long term profit margin and a lower future P/E multiple. What’s in the News for Sensus Healthcare Sensus Healthcare reported that from January 1, 2026 to March 31, 2026, the company repurchased 0 shares under its existing buyback program.Actualización de narrativa • Jun 04
SRTS: 2026 Reimbursement Codes Will Support Long Term Earnings Potential
Analysts have reduced their price target on Sensus Healthcare by $1 to $6, reflecting a lower fair value estimate and sharply reduced profit margin assumptions, partly offset by expectations for continued revenue growth from the SRT platform, supported by new reimbursement codes planned for 2026. Analyst Commentary Recent research points to a more cautious tone around Sensus Healthcare, with the trimmed price target reflecting reduced profit margin assumptions, even as analysts still factor in potential revenue contribution from the SRT platform and future reimbursement changes planned for 2026.Actualización de narrativa • May 19
SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset
Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.
Actualización de narrativa • Apr 25
SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside
Narrative Update Overview Analysts have trimmed their average price target on Sensus Healthcare from $8.00 to $7.50, reflecting mixed views that balance expectations for stronger SRT platform revenue supported by new 2026 reimbursement codes, alongside the impact of recent quarterly results that fell short due to no sales from a key customer. Analyst Commentary Bullish analysts remain constructive on Sensus Healthcare, pointing to the company’s SRT platform and upcoming reimbursement changes as key elements that could support long term growth.Actualización de narrativa • Apr 10
SRTS: 2026 Reimbursement Shift Will Support Future Skin Therapy Adoption
Analysts have updated the price target range for Sensus Healthcare. One analyst raised the target to $7.50, citing expectations for SRT platform revenue supported by new 2026 reimbursement codes.Actualización de narrativa • Mar 27
SRTS: Reimbursement Shift In 2026 Will Drive Future Upside Potential
Narrative Update: Sensus Healthcare (SRTS) The blended analyst price target for Sensus Healthcare has shifted from $8 to $7.50. Analysts are balancing expectations for very strong SRT platform revenue in 2026, tied to new reimbursement codes, with the impact of Q4 results that missed forecasts due to no sales from the company’s largest customer.Actualización de narrativa • Mar 10
SRTS: Future Upside Will Depend On 2026 Reimbursement Code Changes
Analysts have nudged their fair value estimate for Sensus Healthcare slightly higher to $6.88, reflecting mixed recent research in which one firm trimmed its price target to $6 after weak Q4 results, while another initiated coverage with a more upbeat $7.50 target tied to expectations for the SRT platform and 2026 reimbursement changes. Analyst Commentary Bullish Takeaways Bullish analysts point to the SRT-100/Vision platform as the core driver of the current fair value view, given its focus on treating both oncological and non-oncological skin conditions, which supports their more constructive stance on long term growth potential.Actualización de narrativa • Feb 24
SRTS: Future Upside Will Hinge On Reducing Largest Customer Concentration Risk
Narrative Update on Sensus Healthcare Analysts have trimmed their price target on Sensus Healthcare to $6 from $8, pointing to Q4 results that came in well below their expectations after the company reported no sales from its largest customer. Analyst Commentary Analysts are adjusting their views on Sensus Healthcare after the latest Q4 report, with the lower price target reflecting both execution concerns and how the market may now be valuing the shares.Artículo de análisis • Feb 15
Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates
As you might know, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) last week released its latest annual, and things did not...Actualización de narrativa • Feb 10
SRTS: Auditor Transition And Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Sensus Healthcare to US$20.65 from US$21.29, reflecting updated assumptions that include slightly higher projected revenue growth, a modestly stronger profit margin profile, and a marginally lower future P/E multiple. What's in the News Auditor change: Sensus Healthcare's Audit Committee dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP and approved Carr, Riggs & Ingram, LLC as the new independent registered public accounting firm following CRI's acquisition of certain BPB capital markets assets, effective January 1, 2026 (Key Developments).Actualización de narrativa • Jan 25
SRTS: Slightly Improved Outlook And Auditor Transition Will Support Future Upside
Analysts have raised their price target on Sensus Healthcare by a small amount, citing slightly higher assumptions for revenue growth and profit margins, along with a modestly lower discount rate and a marginally reduced future P/E multiple. What's in the News The Audit Committee of Sensus Healthcare's Board of Directors dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent registered public accounting firm and approved Carr, Riggs & Ingram, LLC as the new auditor, following CRI's acquisition of certain capital markets assets from BPB effective January 1, 2026 (company filing).Artículo de análisis • Jan 14
Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares have been powering on, with a gain of 38...Actualización de narrativa • Jan 10
SRTS: Keloid Treatment Breakthrough Will Support Stronger Prospects Despite Trimmed Outlook
Narrative Update on Sensus Healthcare Analysts have modestly raised their price target on Sensus Healthcare, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E. Together, these adjustments support a higher fair value estimate now framed at US$8.00.Actualización de narrativa • Dec 26
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have modestly lifted their price target on Sensus Healthcare to reflect slightly faster expected revenue growth and improving profit margins, even as they temper future valuation multiples. Valuation Changes Discount Rate has risen slightly from 7.69% to 7.70%, reflecting a marginally higher required return.Actualización de narrativa • Dec 12
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have trimmed their price target on Sensus Healthcare to approximately 8 dollars from about 10 dollars, citing softer expected revenue growth, lower projected profit margins, and a higher assumed future price to earnings multiple that together point to a more conservative valuation outlook. What's in the News Peer reviewed data from a single center retrospective study in Dermatologic Therapy show that Sensus Healthcare's superficial radiotherapy technology combined with punch excision significantly improved keloid outcomes over one year, including reductions in pain, itching, thickness and irregularity of scars, with no severe adverse reactions reported (study in Dermatologic Therapy).Artículo de análisis • Nov 19
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rockets 26% But Many Are Still Ignoring The Company
The Sensus Healthcare, Inc. ( NASDAQ:SRTS ) share price has done very well over the last month, posting an excellent...Artículo de análisis • Oct 04
Insufficient Growth At Sensus Healthcare, Inc. (NASDAQ:SRTS) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) is a stock...Actualización de narrativa • Sep 04
Increased CMS Reimbursement And International Expansion Will Unlock Demand
With no new analyst reasoning provided and both the discount rate and future P/E ratio remaining stable, the consensus fair value for Sensus Healthcare is unchanged at $8.00. What's in the News Sensus Healthcare's entire superficial radiation therapy (SRT) system portfolio received Medical Device Single Audit Program (MDSAP) certification.Artículo de análisis • Jul 12
Returns On Capital Are Showing Encouraging Signs At Sensus Healthcare (NASDAQ:SRTS)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Artículo de análisis • May 06
Why Sensus Healthcare, Inc. (NASDAQ:SRTS) Could Be Worth Watching
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it received a lot of...Artículo de análisis • Mar 13
Investors Shouldn't Be Too Comfortable With Sensus Healthcare's (NASDAQ:SRTS) Earnings
Despite posting some strong earnings, the market for Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) stock hasn't moved much...Artículo de análisis • Feb 25
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares are down a considerable 27% in...Artículo de análisis • Feb 08
Revenue Beat: Sensus Healthcare, Inc. Beat Analyst Estimates By 5.6%
Shareholders in Sensus Healthcare, Inc. ( NASDAQ:SRTS ) had a terrible week, as shares crashed 29% to US$5.84 in the...Nueva narrativa • Jan 07
SRTS Market Outlook
Sensus Healthcare (NASDAQ: SRTS) operates in the Healthcare sector and is part of the Medical Devices industry. Specifically, it focuses on the development and commercialization of non-invasive SuperfArtículo de análisis • Dec 18
We Think Sensus Healthcare (NASDAQ:SRTS) Might Have The DNA Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Artículo de análisis • Nov 19
Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders of Sensus Healthcare, Inc. ( NASDAQ:SRTS ) will be pleased this week, given that the stock price is up 19...Artículo de análisis • Nov 12
Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
It's not a stretch to say that Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) price-to-earnings (or "P/E") ratio of 17.4x...Artículo de análisis • Oct 03
At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it saw a significant share...
Nueva narrativa • Sep 28
Fair Deal Agreement And Global Expansion Set To Revolutionize Revenue And Margins
Strategic shift towards recurring revenue with the Fair Deal Agreement model indicates potential for significant revenue growth from 2025.Artículo de análisis • May 12
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Artículo de análisis • Apr 16
Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
With a price-to-sales (or "P/S") ratio of 2.1x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) may be sending bullish signals...Artículo de análisis • Feb 11
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The investors in Sensus Healthcare, Inc. 's ( NASDAQ:SRTS ) will be rubbing their hands together with glee today, after...Rentabilidad de los accionistas
| SRTS | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 4.1% | 1.4% | 1.6% |
| 1Y | -34.1% | -21.6% | 21.1% |
Rentabilidad vs. Industria: Los resultados de SRTS fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -21.6% el año pasado.
Rentabilidad vs. Mercado: SRTS obtuvo unos resultados inferiores a los del mercado US, que fueron del 21.1% el año pasado.
Volatilidad de los precios
| SRTS volatility | |
|---|---|
| SRTS Average Weekly Movement | 10.1% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: SRTS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SRTS (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2010 | 60 | Joe Sardano | sensushealthcare.com |
Sensus Healthcare, Inc. es una empresa de productos sanitarios que fabrica y vende dispositivos de radioterapia a profesionales sanitarios de todo el mundo. La empresa utiliza la radioterapia superficial, una tecnología de rayos X de baja energía, en su cartera de dispositivos de tratamiento. Ofrece SRT-100, un sistema de radioterapia superficial de rayos X fotónicos de baja energía que proporciona a los pacientes una alternativa a la cirugía para el tratamiento de cánceres de piel no melanoma, incluidos los cánceres de piel de células basales y de células escamosas, así como otras afecciones cutáneas, como los queloides; y SRT-100 Vision, que proporciona al usuario una aplicación de planificación del tratamiento de radioterapia superficial adaptada que integra un módulo de imágenes por ultrasonidos de alta frecuencia, análisis volumétrico del tumor, planificación de los márgenes del haz y parámetros de dosimetría.
Resumen de fundamentos de Sensus Healthcare, Inc.
| Estadísticas fundamentales de SRTS | |
|---|---|
| Capitalización bursátil | US$49.88m |
| Beneficios(TTM) | -US$7.77m |
| Ingresos (TTM) | US$22.53m |
2.2x
Ratio precio-ventas (PS)-6.5x
Ratio precio-beneficio (PE)¿Está SRTS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SRTS | |
|---|---|
| Ingresos | US$22.53m |
| Coste de los ingresos | US$14.03m |
| Beneficio bruto | US$8.50m |
| Otros gastos | US$16.28m |
| Beneficios | -US$7.77m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.47 |
| Margen bruto | 37.74% |
| Margen de beneficio neto | -34.50% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado SRTS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/02 21:52 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Sensus Healthcare, Inc. está cubierta por 8 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Scott Henry | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |